中国基层医药
中國基層醫藥
중국기층의약
CHINESE JOURNAL OF PRIMARY MEDICINE AND PHARMACY
2013年
13期
1996-1998
,共3页
哮喘%孟鲁司特%肿瘤坏死因子α%免疫球蛋白E%白细胞介素6%儿童
哮喘%孟魯司特%腫瘤壞死因子α%免疫毬蛋白E%白細胞介素6%兒童
효천%맹로사특%종류배사인자α%면역구단백E%백세포개소6%인동
Asthma%Montelukast%Tumor necrosis factor-alpha%Immunoglobulin E%Interleukin-6%Child
目的 探讨孟鲁司特在小儿轻度哮喘中的应用效果.方法 将120例轻度哮喘患儿按照治疗方法的不同分为治疗组和对照组,对照组采用常规治疗,治疗组在对照组的基础上采用孟鲁司特治疗,两组均治疗4周为1个疗程.结果 治疗组的总有效率为91.7％,显著高于对照组的73.3％(x2=3.89,P＜0.05).治疗组的日间和夜间哮喘评分分别为(0.13±0.05)分、(0.12±0.04)分,显著低于对照组的(1.13±0.21)分、(0.43±0.23)分,无症状天数为(17.43 ±2.87)d,显著长于对照组的(9.34±1.57)d(=2.32、1.97、5.75,均P ＜0.05).治疗组治疗后的白细胞介素6(IL-6)、肿瘤坏死因子α(TNF-α)、免疫球蛋白E(IgE)分别为(140.5 ±6.4) ng/L、(40.1±4.9)IU/ml、(105.6±8.8)IU/ml,显著低于对照组的(189.3±9.7)ng/L、(78.6±7.5)IU/ml、(155.4±10.5) IU/ml(t=11.97、8.75、13.56,均P＜0.05).治疗组的不良反应发生率为13.3％,与对照组的10.0％差异无统计学意义(x2=1.32,P＞0.05).结论 孟鲁司特能够显著改善轻度哮喘患儿的炎性状态,缓解患儿的临床症状,且不良反应少.
目的 探討孟魯司特在小兒輕度哮喘中的應用效果.方法 將120例輕度哮喘患兒按照治療方法的不同分為治療組和對照組,對照組採用常規治療,治療組在對照組的基礎上採用孟魯司特治療,兩組均治療4週為1箇療程.結果 治療組的總有效率為91.7％,顯著高于對照組的73.3％(x2=3.89,P＜0.05).治療組的日間和夜間哮喘評分分彆為(0.13±0.05)分、(0.12±0.04)分,顯著低于對照組的(1.13±0.21)分、(0.43±0.23)分,無癥狀天數為(17.43 ±2.87)d,顯著長于對照組的(9.34±1.57)d(=2.32、1.97、5.75,均P ＜0.05).治療組治療後的白細胞介素6(IL-6)、腫瘤壞死因子α(TNF-α)、免疫毬蛋白E(IgE)分彆為(140.5 ±6.4) ng/L、(40.1±4.9)IU/ml、(105.6±8.8)IU/ml,顯著低于對照組的(189.3±9.7)ng/L、(78.6±7.5)IU/ml、(155.4±10.5) IU/ml(t=11.97、8.75、13.56,均P＜0.05).治療組的不良反應髮生率為13.3％,與對照組的10.0％差異無統計學意義(x2=1.32,P＞0.05).結論 孟魯司特能夠顯著改善輕度哮喘患兒的炎性狀態,緩解患兒的臨床癥狀,且不良反應少.
목적 탐토맹로사특재소인경도효천중적응용효과.방법 장120례경도효천환인안조치료방법적불동분위치료조화대조조,대조조채용상규치료,치료조재대조조적기출상채용맹로사특치료,량조균치료4주위1개료정.결과 치료조적총유효솔위91.7％,현저고우대조조적73.3％(x2=3.89,P＜0.05).치료조적일간화야간효천평분분별위(0.13±0.05)분、(0.12±0.04)분,현저저우대조조적(1.13±0.21)분、(0.43±0.23)분,무증상천수위(17.43 ±2.87)d,현저장우대조조적(9.34±1.57)d(=2.32、1.97、5.75,균P ＜0.05).치료조치료후적백세포개소6(IL-6)、종류배사인자α(TNF-α)、면역구단백E(IgE)분별위(140.5 ±6.4) ng/L、(40.1±4.9)IU/ml、(105.6±8.8)IU/ml,현저저우대조조적(189.3±9.7)ng/L、(78.6±7.5)IU/ml、(155.4±10.5) IU/ml(t=11.97、8.75、13.56,균P＜0.05).치료조적불량반응발생솔위13.3％,여대조조적10.0％차이무통계학의의(x2=1.32,P＞0.05).결론 맹로사특능구현저개선경도효천환인적염성상태,완해환인적림상증상,차불량반응소.
Objective To investigate the application effect of montelukast in children with mild asthma.Methods 120 patients with mild asthma were randomly divided into the treatment group and the control group,the control group was given conventional therapy,the treatment group was treated with montelukast on the basis of the control group.Two groups were treated for 4 weeks as a course.Results The total effective rate of treatment group was 91.7％,which was significantly higher than 73.3％ in the control group (x2 =3.89,P ＜0.05).The daytime and nighttime asthma score in the treatment group were (0.13 ± 0.05)points,(0.12 ± 0.04)points,which were significantly lower than (1.13 ± 0.21) points,(0.43 ± 0.23) points in the control group.The symptom-free days was (17.43 ± 2.87) d,which was significantly longer than (9.34 ± 1.57) d in the control group(t =2.32,1.97,5.75,all P ＜ 0.05).IL-6,TNF-α,IgE in the treatment group after the treatment were (140.5 ± 6.4) ng/L,(40.1 ± 4.9) IU/ml,(105.6 ± 8.8) IU/ml,which were significantly lower than (189.3 ± 9.7) ng/L,(78.6 ± 7.5) 1U/ml,(155.4 ±10.5) IU/ml in the control group (t =11.97,8.75,13.56,all P ＜ 0.05).The incidence rate of adverse reaction in the treatment group was 13.3％ and 10％ in the control group,there was no significant ditterence(x2 =1.32,P ＞0.05).Conclusion Montelukast can significantly improve the inflammatory state in children with mild asthma,relieve clinical symptoms,improve the therapeutic effect,and has less adverse reactions.
